Recalcitrant alopecia areata responsive to leflunomide and anthralin-Potentially undiscovered JAK/STAT inhibitors?
| Autor: | Kabir Sardana, Ram Krishan Gautam, Aastha Gupta |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Adolescent Alopecia Areata Administration Topical Dermatology Disease Pathogenesis 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Humans Janus Kinase Inhibitors Medicine Leflunomide 030203 arthritis & rheumatology business.industry JAK-STAT signaling pathway Isoxazoles Anthralin Alopecia areata medicine.disease Crosstalk (biology) Treatment modality Pediatrics Perinatology and Child Health Cancer research Dermatologic Agents business CD8 Hair medicine.drug |
| Zdroj: | Pediatric Dermatology. 35:856-858 |
| ISSN: | 0736-8046 |
| Popis: | Several treatment modalities are available for the management of alopecia areata (AA); however, no therapy is universally effective and treatment can be frustrating in severe cases, with low response and high recurrence rates. Recent studies show that the JAK/STAT pathway plays a central role in the pathogenesis of this disease by determining the crosstalk between the infiltrating CD8+ T cells and the hair follicles, suggesting a role of JAK inhibitors in the treatment of AA. However, reports on the off-label use of these more expensive targeted agents have shown variable results. We present a case of a child with recalcitrant ophiasis-pattern AA who had failed steroid therapy and was treated successfully with leflunomide and anthralin, possibly by the synergistic effect on the JAK/STAT pathway inhibition, and we propose this combination could be a cost-effective therapeutic option for recalcitrant AA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text